Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.
Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, Ohki M, Tsudaka S, Date K, Matsuda N, Iwata K, Zhu Y, Nakata K, Shien K, Yamamoto H, Nakayama A, Okazaki M, Sugimoto S, Toyooka S. Takatsu F, et al. Among authors: date k. J Mol Med (Berl). 2023 Dec;101(12):1603-1614. doi: 10.1007/s00109-023-02384-7. Epub 2023 Oct 13. J Mol Med (Berl). 2023. PMID: 37831111
Correction to: Periostin secreted by cancer‑associated fibroblasts promotes cancer progression and drug resistance in non‑small cell lung cancer.
Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, Ohki M, Tsudaka S, Date K, Matsuda N, Iwata K, Zhu Y, Nakata K, Shien K, Yamamoto H, Nakayama A, Okazaki M, Sugimoto S, Toyooka S. Takatsu F, et al. Among authors: date k. J Mol Med (Berl). 2024 Jan;102(1):147. doi: 10.1007/s00109-023-02408-2. J Mol Med (Berl). 2024. PMID: 38105305 No abstract available.
PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
Thu YM, Suzawa K, Tomida S, Ochi K, Tsudaka S, Takatsu F, Date K, Matsuda N, Iwata K, Nakata K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Toyooka S. Thu YM, et al. Among authors: date k. PLoS One. 2024 May 17;19(5):e0300644. doi: 10.1371/journal.pone.0300644. eCollection 2024. PLoS One. 2024. PMID: 38758826 Free PMC article.
Prognostic performance of microscopic size measurements in small invasive carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas.
Zhang ML, Omori Y, Hong SM, Ideno N, Date K, Rocha Castellanos DM, Shroff SG, Zamboni G, Gonzalez RS, Furukawa T, Fernandez-Del Castillo C, Mino-Kenudson M. Zhang ML, et al. Among authors: date k. Histopathology. 2024 Apr 25. doi: 10.1111/his.15198. Online ahead of print. Histopathology. 2024. PMID: 38660970
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Takei S, et al. Among authors: date k. Front Immunol. 2024 Feb 23;15:1348034. doi: 10.3389/fimmu.2024.1348034. eCollection 2024. Front Immunol. 2024. PMID: 38464519 Free PMC article.
230 results